The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function - ScienceDirect
A Comprehensive Review of PCSK9 Inhibitors - Caroline Coppinger, Mohammad Reza Movahed, Veronica Azemawah, Lee Peyton, James Gregory, Mehrnoosh Hashemzadeh, 2022
Lipid lowering with PCSK9 inhibitors | Nature Reviews Cardiology
PCSK9 Inhibitors Topic Review | Learn the Heart
PCSK9 Inhibition: The Big Step Forward in Lipid Control | ECR Journal
F.D.A. Approves Repatha, a Second Drug for Cholesterol in a Potent New Class - The New York Times
PCSK9 and its Inhibitors: A new approach in lipid lowering therapy | BioVendor R&D
Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome - ScienceDirect
Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives | Acta Pharmacologica Sinica
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
JCM | Free Full-Text | Soluble PCSK9 Inhibition: Indications, Clinical Impact, New Molecular Insights and Practical Approach—Where Do We Stand?
PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions - ScienceDirect
Frontiers | Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Frontiers | PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
PCSK9 Inhibitors: Ushering in a new era of Cholesterol Busters. A Comprehensive Review. - Kindle edition by Saboowala, Dr. Hakim, Saboowala, Dr. Hakim. Professional & Technical Kindle eBooks @ Amazon.com.
PCSK9 Inhibitors: Ushering in a new era of Cholesterol Busters. A Comprehensive Review. - Kindle edition by Saboowala, Dr. Hakim, Saboowala, Dr. Hakim. Professional & Technical Kindle eBooks @ Amazon.com.
Statins and PCSK9 inhibitors: A new lipid-lowering therapy - ScienceDirect
Lipid-Lowering Therapy and Hemorrhagic Stroke Risk | Stroke
The Evolving Future of PCSK9 Inhibitors | Journal of the American College of Cardiology
Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor | Arteriosclerosis, Thrombosis, and Vascular Biology
Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment | Journal of Medicinal Chemistry
Cells | Free Full-Text | PCSK9 Inhibition: From Current Advances to Evolving Future
Advances in Statin Therapy and Beyond in CVD (ASTC): A Textbook of Cardiology: Chopra, H. K., Nanda, Navin C., Narula, Jagat, Wander, GS, Manjunath, CN: 9789354653933: Amazon.com: Books
PCSK9 inhibitors: A new era of lipid lowering therapy
